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50 to 90. The melanocyte density was expressed as the average
number of melanocytes per mm2.
Quantitative studies on melanocytes have been done in both
humans and animals using the DOPA reaction (Szabo, 1954;
Breathnach, 1957; Staricco and Pinkus, 1957). We report on the
direct in vivo examination of melanocytes. In vivo examination
avoids potential artifacts introduced by biopsy, the removal of the
dermis from the epidermis, and staining with DOPA or Fontana±
Masson. In vivo examination also avoids potential artifact induced
by ®xation with the associated shrinkage of cells and tissue.
Melanocytes in the wing and interfemoral membranes of the bat
and in the ear of the mouse have been examined in vivo by
transmitted light (McGuire, 1966; Snell et al, 1966). RCM may be
used to investigate melanocytes on any body part in any animal.
Melanin provided strong contrast in RCM images. Therefore,
pigmented cells appeared bright. For the purpose of comparison,
re¯ectance confocal images were inverted to print a ``negative.''
Fig 1 shows images from RCM, DOPA, and Fontana±Masson
staining from the back.
We compared our results from re¯ectance confocal images with
conventional DOPA staining. The data are summarized in Table I.
Melanocyte characteristics such as cell body area, number of
dendrites, and length of longest dendrite were measured in RCM
and DOPA images using an image processing and analysis program.
Melanocyte characteristics exhibited a large SD, re¯ecting inherent
variation. This was consistent with previously reported data
(Bischitz and Snell, 1959). Using Student's t test, there was no
statistically signi®cant difference between melanocyte features from
RCM and DOPA images.
On the back, melanocyte counts by RCM images were
consistently lower than by DOPA images. Our criteria for counting
a melanocyte required visualization of a cell body and at least one
dendrite. At times, we identi®ed structures that were likely
dendrites in RCM, but were unable to visualize the associated
cell body. Therefore, RCM melanocyte counts were underesti-
mates.
In the ear, only scattered melanocytes were visualized on RCM
images. Figure 2 shows RCM, DOPA, and Fontana±Masson
images from the ear. It was not possible to assess melanocyte density
in RCM images of the ear. From inspection of the Fontana±
Masson images, there are more melanin granules in ear keratino-
cytes than back keratinocytes. We hypothesized that melanin
granules are more ef®ciently transferred to keratinocytes in the ear
compared with the back. Therefore, melanocytes were not well
demarcated in the ear. We assessed the melanin content of RCM
images by examining the distribution of gray values using image
analysis. RCM images of the ear had higher gray values compared
with images from the back. These data suggested that keratinocytes
from the ear contained more melanin than those from the back.
DOPA images of the ear showed that melanocyte cell counts were
about three times greater than on the back, consistent with
previously reported data (Bischitz and Snell, 1959; Wolff and
Winkelman, 1967).
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Exclusion of Candidate Genes and Loci for Multiple
Lentigines Syndrome
To the Editor: Multiple lentigines syndrome (MLS) is an autosomal dominant
disorder of variable penetrance and expressivity. MLS is associated
with generalized skin and mucosal pigmentation abnormalities called
lentigines (Arnsmeier and Paller, 1996; Uhle and Norvell, 1988).
Lentigines manifest histologically as a hyperproliferation of melano-
cytes along the dermal±epidermal junction. MLS has also appeared
with other noncutaneous manifestations, mainly cardiac, auditory,
and developmental abnormalities. It is thought to be a variant of the
autosomal dominant LEOPARD syndrome (MIM151100)
(Arnsmeier and Paller, 1996), which includes Lentigines, ECG
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abnormalities, Ocular hypertelorism/Obstructive cardiomyopathy,
Pulmonary valve stenosis, Abnormalities of genitalia in males,
Retardation of growth, and Deafness (Gorlin et al, 1969).
Clinically, MLS is commonly grouped with the lentiginosis
syndromes. These syndromes combine the cutaneous ®ndings of
lentigines with a variety of developmental defects of the
cardiovascular, endocrine, gastrointestinal, and nervous systems as
well as increased susceptibility to tumorigenesis (Stratakis, 2000).
The other lentiginosis syndromes include Peutz±Jeghers syndrome
(MIM175200), the Carney complex (MIM160980), Cowden
syndrome (MIM158350), and Bannayan±Zonana syndrome
(MIM153480). Multiple lentigines have also been associated with
neuro®bromatosis type 1 (NF-1) (MIM162200) and Noonan
syndrome (MIM 163950). MLS and NF-1 share cafeÂ-au-lait
patches and growth retardation and these two disorders should be
included in the differential diagnosis of a patient with pigmentation
anomalies and development defects (Coppin and Temple, 1997).
Noonan syndrome and MLS overlap with certain clinical mani-
festations such as lentigines, cafeÂ-au-lait patches, and developmental
cardiac defects, such as pulmonary valve dyplasia and cardiomyo-
pathies. Some researchers have suggested that both syndromes may
be part of a common spectrum (Blieden et al, 1983; Mendez and
Opitz, 1985; Coppin and Temple, 1997; Tullu et al, 2000).
Few detailed molecular studies of the MLS have been performed.
A de novo mis-sense mutation in neuro®bromin was identi®ed in a
patient with clinical overlapping features of NF1 and MLS (Wu et
al, 1996); however, another study in a small family with MLS
demonstrated no evidence of linkage to the NF1 locus (Ahlbom et
al, 1995). To identify the gene(s) responsible for MLS, we
performed a linkage study in a large affected family. Candidate
genes or loci were studied that may be involved in other
phenotypes that share some similarity to the disorder under study.
SUBJECTS AND METHODS
The Colorado Multiple Institutional Review Board approved the
project. Diagnosis of MLS in affected family members was based on
Figure 1. Pedigree of the family showing an autosomal dominant inheritance.
Table I. Disease loci, candidate genes, and their maximum LOD scores for MLS
Disease locus
Gene symbol,
chromosome localization Protein Function
Markers
(Marsh®eld location)
Maximum
multipoint LOD
Neuro®bromatosis 1
D17S1857 (43.01)
NF 1,
±3.51
17q11.2
Neuro®bromin involved in the RAS
signal transduction
pathway
Tumor suppressor
NF1 (51.9±58.8)
D17S798 (53.41)
D17S1868 (64.16)
±4.13
±6.60
Carney
locus 1
N/A,
2p16
D2S337 (80.69) D2S2259 (64.29)
D2S391 (70.31)
±3.75
±4.53
±4.09
Carney PRKAR1A Type I regulatory Dominant negative D17S944 (82.59) ±6.37
locus 2 17q23±q24 a subunit of regulator of PRKAR1A (90.2)
cyclic adenosine
monophosphate
dependent protein
kinase (protein
kinase A)
transcription in
somatic cell hybrids
D17S949 (93.27) ±4.52
Peutz±Jeghers
locus 1
STK11/LKB1
19p13.3
Serine/threonine
kinase 11
Cytosolic protein that
has growth inhibitory
activity
D19S886 (0)
STK11/LKB1 (0±31.9)
D19S209 (10.97)
D19S216 (20.01)
±3.45
±3.76
±6.46
Peutz±Jeghers
locus 2
N/A
19p13.4
D19S418 (92.56)
D19S210 (100.01)
±3.29
±4.05
Cowden/
Bannayan±Zonana
locus
PTEN
10q23
Dual speci®city
phosphatase
(tensin homolog)
Putative tumor
suppressor
D10S537 (91.13)
PTEN (107.3±114.3)
D10S185 (116.34)
±4.66
±5.30
Noonan syndrome
locus
PTPN11
12q24.1
Protein tyrosine
phosphate SHP±2
Contains two
Src homology
2 (SH2) domains
D12S78 (111.87)
PTPN11 (114.3±125.3)
D12S79 (125.31)
±3.81
±6.40
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the presence of multiple small 1±5 mm hyperpigmented macules
on the entire body sparing the palmar and plantar surfaces. Family
members were deemed unaffected if no hyperpigmented macules
were present.
DNA was prepared from peripheral blood samples using the
Qiagen Maxi kit (Qiagen, Valencia, CA). Twenty-four family
members were genotyped for microsatellite markers ¯anking each
of the candidate genes on chromosomes 2, 10, 12, 17, and 19.
Markers were ampli®ed using a PE Biosystems 877 Catalyst
(Applied Biosystems), pooled in panels of 10±20 markers, and
products were separated by electrophoresis in 5% polyacrylamide
gels using a PE Biosystems 377 semiautomated sequencer. Allele
sizing was carried out using GENESCAN 3.1 (Applied
Biosystems), and individual genotypes were assigned using
GENOTYPER 2.5 (Applied Biosystems), with manual checking
to minimize data errors.
Two-point parametric LOD scores were calculated using
MLINK (Cottingham et al, 1993) under assumptions of an
autosomal dominant trait, disease gene frequency of 0.0001 and
penetrance of 1.0 or 0.8. Multipoint parametric LOD scores were
calculated using GENEHUNTER 2.1 (Kruglyak et al, 1996).
RESULTS
As shown in Fig 1, 13 members of this Hispanic family in four
generations exhibited multiple lentigines inherited in a monogenic,
autosomal dominant pattern.
Age of onset of the lentigines in family members is typically 2 y
of age. Self-reported medical histories of examined affected family
members revealed one relative affected with alopecia areata, two
relatives affected with hearing impairments (one patient has
Williams syndrome and the hearing loss in the other was attributed
to a premature birth), and three relatives affected with unde®ned
learning disabilities. Biopsies of select lesions revealed the
histopathologic presence of increased numbers of melanocytes
along the dermal±epidermal junction. No evidence of other
phenotypic features of LEOPARD syndrome were observed in
any of the observed affected family members.
A linkage screen of chromosomes 2, 10, 12, 17, and 19 was
performed using markers within and/or ¯anking MLS candidate
genes or loci (Table I). Two-point and multipoint parametric
linkage analysis provided no evidence for linkage to a number of
chromosomal regions on chromosomes 2, 10, 12, 17, and 19. The
LOD scores for genetic markers ¯anking PTEN, NF1, STK11/
LKB1, PRKAR1A, PTPN11, Carney locus 1, and Peutz±Jeghers
locus 2 are <3. Therefore, these genes and loci can be excluded as
the cause of MLS in this family.
There are no published reports of Williams syndrome and MLS
manifesting in the same patient. Although Williams syndrome and
MLS share some similar phenotypic features (e.g., dental and
craniofacial anomalies, pulmonary stenosis, cardiovascular anomal-
ies, short stature, and developmental delay), linkage analysis showed
LOD scores of ± 3.98 and ± 1.12 for the ¯anking markers, D7S502
and D7S630 of the Williams±Beuren syndrome (Online
Mendelian, MIM194050) locus (Wang et al, 1999).
Homozygosity for polymorphic markers ¯anking the Williams
syndrome region at 7q11.2 con®rmed the presence of a de novo
deletion in the affected patient.
DISCUSSION
We describe an autosomal dominant disorder characterized by the
early onset of multiple cutaneous lentigines. Linkage excluded
candidate genes or loci for this disorder to chromosomal loci
associated with similar clinical and pathologic features. The cause of
MLS or LEOPARD syndrome is unknown. The spectrum of
noncutaneous abnormalities associated with MLS is vast.
Predominant noncutaneous abnormalities include obstructive
cardiomyopathies, sensorineural deafness, and developmental de®-
ciencies. The true incidence of noncutaneous features of MLS is
dif®cult to assess because the clinical descriptions are often
incomplete. Family histories are not always provided and when
included, often only discuss individuals with lentigines. The
literature suggests that MLS manifests in three ways: (i) sporadic
with no family history; (ii) autosomal dominant with affected family
members with cutaneous and variable noncutaneous manifestation;
and (iii) autosomal dominant with affected family members with
only cutaneous manifestations (Voron et al, 1976; Arnsmeier and
Paller, 1996; Uhle and Norvell, 1988). Additionally, numerous
clinical reports identify a patient with LEOPARD syndrome and
associate other family members with lentigines (Matthews, 1968;
Polani and Moynahan, 1972; Seuanez et al, 1976; Peixoto et al,
1981; Loyd et al, 1982; Bleiden et al, 1983; Malathi et al, 1985;
Choi et al, 1998). These reports of families with only generalized
lentigines highlight the clinical dilemma of monitoring patients and
their families for internal associations, especially cardiac and
auditory abnormalities (Arnsmeier and Paller, 1996; Uhle and
Norvell, 1988). Further molecular genetic studies are needed to
determine whether MLS and LEOPARD are the same syndrome
or distinct entities. The current family is being studied to establish
linkage and to identify the responsible gene.
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